5 Best 52-Week High US Stocks to Buy

3. Xenon Pharmaceuticals Inc (NASDAQ:XENE)

Stock Price as of April 21: $56.48

52-Week Range: $28.19 – $63.95

Stock Upside Potential: 27.01%

Number of Hedge Fund Holders: 55

Xenon Pharmaceuticals Inc (NASDAQ:XENE) is among the best 52-week high US stocks to buy. On April 19, Xenon Pharmaceuticals Inc (NASDAQ:XENE) presented data from the Phase 3 X-TOLE2 study of its epilepsy drug candidate, azetukalner, at the American Academy of Neurology Annual Meeting in Chicago.

Xenon used the event to highlight the study’s strong results. It also used the platform to talk about its plans to seek regulatory approval for azetukalner.

In the late-stage study, patients treated with azetukalner showed a 53.2% reduction in monthly seizure frequency at the 25 mg dose. At the 15 ​mg dose, the monthly seizure frequency reduced by 34.5%. Those in the placebo group showed a 10.4% reduction.

Some patients achieved complete seizure control. Xenon revealed that the rate of 100% seizure reduction increased over time as patients remained in the therapy. In the final four weeks of the trial, 13.7% of patients in the 25 mg group and 12.8% of those in the 15 mg group achieved complete seizure control. That compared to 4.0% for the placebo group.

The study enrolled patients with treatment-resistant epilepsy who had around 12.75 seizures per month and had tried around five anti-seizure medications before.

Xenon plans to file for FDA approval of azetukalner in Q3 2026, with a decision expected in late 2027 or early 2028. On March 9, Reuters reported that analysts were estimating over $2 billion in peak sales for azetukalner if approved.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders, including epilepsy and depression. It has several potential drug products in the pipeline. The company is based in Canada, but it also has offices in the US.